Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies

Elena Raschi, Valentina Broggini, Claudia Grossi, M. Orietta Borghi, Silvia S. Pierangeli, Pier Luigi Meroni

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Antiphospholipid antibodies (aPL) are both diagnostic and pathogenic antibodies. aPL may: (1) interfere with anticoagulant mechanisms and fibrinolysis favoring a prothrombotic state, and (2) interact with cells of the coagulation cascade (i.e. endothelial cells, monocytes, and platelets) inducing a procoagulant phenotype. These pathogenic mechanisms have been reproduced in in vivo animal models. Thrombotic events explain in part the fetal losses associated with antiphospholipid syndrome (APS) and additional aPL-mediated mechanisms have been described that may contribute a defective placenta without placental thrombosis. A direct aPL interaction with kidney endothelial cells or with neuronal cells has been suggested to explain additional non-thrombotic manifestations of the syndrome, such as APS nephropathy and brain involvement with no clear signs of ischemic events. Finally, aPL have been shown to activate complement in both in vivo and in vitro experimental models. Whether or not such mechanisms play a role in APS patients is still a matter of research.

Original languageEnglish
Pages (from-to)55-67
Number of pages13
JournalHandbook of Systemic Autoimmune Diseases
Volume10
DOIs
Publication statusPublished - 2009

Fingerprint

Antiphospholipid Antibodies
Antiphospholipid Syndrome
Endothelial Cells
Fibrinolysis
Anticoagulants
Placenta
Monocytes
Thrombosis
Theoretical Models
Blood Platelets
Animal Models
Phenotype
Kidney
Antibodies
Brain
Research

Keywords

  • antiphospholipid antibodies
  • antiphospholipid syndrome
  • beta-2 glycoprotein I
  • fetal loss
  • thrombosis

ASJC Scopus subject areas

  • Immunology
  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy

Cite this

Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies. / Raschi, Elena; Broggini, Valentina; Grossi, Claudia; Orietta Borghi, M.; Pierangeli, Silvia S.; Meroni, Pier Luigi.

In: Handbook of Systemic Autoimmune Diseases, Vol. 10, 2009, p. 55-67.

Research output: Contribution to journalArticle

@article{9d3233b6e6d7465aab85967b9e2014f8,
title = "Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies",
abstract = "Antiphospholipid antibodies (aPL) are both diagnostic and pathogenic antibodies. aPL may: (1) interfere with anticoagulant mechanisms and fibrinolysis favoring a prothrombotic state, and (2) interact with cells of the coagulation cascade (i.e. endothelial cells, monocytes, and platelets) inducing a procoagulant phenotype. These pathogenic mechanisms have been reproduced in in vivo animal models. Thrombotic events explain in part the fetal losses associated with antiphospholipid syndrome (APS) and additional aPL-mediated mechanisms have been described that may contribute a defective placenta without placental thrombosis. A direct aPL interaction with kidney endothelial cells or with neuronal cells has been suggested to explain additional non-thrombotic manifestations of the syndrome, such as APS nephropathy and brain involvement with no clear signs of ischemic events. Finally, aPL have been shown to activate complement in both in vivo and in vitro experimental models. Whether or not such mechanisms play a role in APS patients is still a matter of research.",
keywords = "antiphospholipid antibodies, antiphospholipid syndrome, beta-2 glycoprotein I, fetal loss, thrombosis",
author = "Elena Raschi and Valentina Broggini and Claudia Grossi and {Orietta Borghi}, M. and Pierangeli, {Silvia S.} and Meroni, {Pier Luigi}",
year = "2009",
doi = "10.1016/S1571-5078(08)00404-2",
language = "English",
volume = "10",
pages = "55--67",
journal = "Handbook of Systemic Autoimmune Diseases",
issn = "1571-5078",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Chapter 4 Mechanisms of Action of Antiphospholipid Antibodies

AU - Raschi, Elena

AU - Broggini, Valentina

AU - Grossi, Claudia

AU - Orietta Borghi, M.

AU - Pierangeli, Silvia S.

AU - Meroni, Pier Luigi

PY - 2009

Y1 - 2009

N2 - Antiphospholipid antibodies (aPL) are both diagnostic and pathogenic antibodies. aPL may: (1) interfere with anticoagulant mechanisms and fibrinolysis favoring a prothrombotic state, and (2) interact with cells of the coagulation cascade (i.e. endothelial cells, monocytes, and platelets) inducing a procoagulant phenotype. These pathogenic mechanisms have been reproduced in in vivo animal models. Thrombotic events explain in part the fetal losses associated with antiphospholipid syndrome (APS) and additional aPL-mediated mechanisms have been described that may contribute a defective placenta without placental thrombosis. A direct aPL interaction with kidney endothelial cells or with neuronal cells has been suggested to explain additional non-thrombotic manifestations of the syndrome, such as APS nephropathy and brain involvement with no clear signs of ischemic events. Finally, aPL have been shown to activate complement in both in vivo and in vitro experimental models. Whether or not such mechanisms play a role in APS patients is still a matter of research.

AB - Antiphospholipid antibodies (aPL) are both diagnostic and pathogenic antibodies. aPL may: (1) interfere with anticoagulant mechanisms and fibrinolysis favoring a prothrombotic state, and (2) interact with cells of the coagulation cascade (i.e. endothelial cells, monocytes, and platelets) inducing a procoagulant phenotype. These pathogenic mechanisms have been reproduced in in vivo animal models. Thrombotic events explain in part the fetal losses associated with antiphospholipid syndrome (APS) and additional aPL-mediated mechanisms have been described that may contribute a defective placenta without placental thrombosis. A direct aPL interaction with kidney endothelial cells or with neuronal cells has been suggested to explain additional non-thrombotic manifestations of the syndrome, such as APS nephropathy and brain involvement with no clear signs of ischemic events. Finally, aPL have been shown to activate complement in both in vivo and in vitro experimental models. Whether or not such mechanisms play a role in APS patients is still a matter of research.

KW - antiphospholipid antibodies

KW - antiphospholipid syndrome

KW - beta-2 glycoprotein I

KW - fetal loss

KW - thrombosis

UR - http://www.scopus.com/inward/record.url?scp=67649977558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649977558&partnerID=8YFLogxK

U2 - 10.1016/S1571-5078(08)00404-2

DO - 10.1016/S1571-5078(08)00404-2

M3 - Article

AN - SCOPUS:67649977558

VL - 10

SP - 55

EP - 67

JO - Handbook of Systemic Autoimmune Diseases

JF - Handbook of Systemic Autoimmune Diseases

SN - 1571-5078

ER -